Results 161 to 170 of about 57,303 (248)

Life Course Malaria Exposure and SARS‐CoV‐2 Seroepidemiology in Ugandan Adolescents: A Longitudinal Study Nested in a Birth Cohort

Tropical Medicine &International Health, Volume 31, Issue 8, Page 1012-1027, August 2026.
ABSTRACT Background COVID‐19 has had major global health impacts, yet reported morbidity and mortality have been lower in Africa despite serological evidence of widespread infection. Malaria has been proposed as a potential modifier of susceptibility to and outcomes of SARS‐CoV‐2 infection.
Ludoviko Zirimenya, Doreen Nayebare, Claire Baine, Jacent Nassuuna, Milly Namutebi, Christopher Zziwa, Denis Nsubuga, Fred Kiwudhu, Florence Akello, Josephine Tumusiime, Gloria Oduru, Grace Kabami, Hellen Akurut, Rachel Nakyesige, Agnes Natukunda, Anne Wajja, Lawrence Lubyayi, Simon Kimuda, Gyaviira Nkurunungi, Jennifer Serwanga, Katie J. Doores, Emily L. Webb, Alison M. Elliott   +22 more
wiley   +1 more source

Divergent macrophage-regulated T cell states determine response to Bacillus Calmette-Guérin vaccine in high-risk bladder cancer. [PDF]

J Clin Invest
Brown RJ, Khan MT, Houston AJ, Niu H, Podojil JR, Choy B, Cui W, Meeks JJ.   +7 more
europepmc   +1 more source

Bacillus Calmette-Guérin (BCG) Vaccination and the Immune-Brain Axis: Implications for Neuroprotection and Neurodegenerative Disease. [PDF]

Vaccines (Basel)
Druszczynska M, Sadowska B, Kulesza J, Kulesza E, Fol M.   +4 more
europepmc   +1 more source

Hybrid-Driven Bacillus Calmette-Guérin Carrier for Targeted Immuno-Chemo Combo Therapy in Bladder Cancer. [PDF]

Cyborg Bionic Syst
Zhang Z, Wang L, An Z, Jiang Y, Niu J, Yang L, Wang Q, Fan X, Li T.   +8 more
europepmc   +1 more source

A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancer. [PDF]

Nanomedicine (Lond)
Narayan A, Leibrandt RC, Lee JS, Dall'Era MA, Whitson JM, Chandrasekar T, Braun A, Mossanen M, Li H, Lara PN, Lam KS, Pan CX, Parikh M.   +12 more
europepmc   +1 more source

The combination of atezolizumab and BCG in high-risk non-muscle invasive bladder cancer: results of the phase Ib/II BladderGATE clinical trial. [PDF]

Oncologist
Guerrero-Ramos F, Gómez-Cañizo C, Rodríguez-Izquierdo M, Hernández-Arroyo M, Rodríguez-Antolín A, de Velasco G, Ponce-Aix S, Paramio JM, Suárez-Cabrera C, Rubio C, Morales L, García-Martínez V, Dueñas M, Castellano D.   +13 more
europepmc   +1 more source

Clinical outcomes of BCG‐treated patients with high‐risk non‐muscle‐invasive bladder cancer according to pre‐ and post‐2021 European Association of Urology risk classifications

BJU International, Volume 138, Issue 2, Page 229-231, August 2026.
Tian Ye, Benjamin Tura, Ben Abbotts, Maurice P. Zeegers, K. K. Cheng, Nicholas D. James, Richard T. Bryan   +6 more
wiley   +1 more source

CHORIORETINITIS AFTER BACILLUS CALMETTE-GUERIN TREATMENT FOR BLADDER CANCER. [PDF]

Retin Cases Brief Rep
Boopathiraj N, Boopathiraj N, Wagner IV, Powers R, Mashayekhi A.   +4 more
europepmc   +1 more source

A proteome-wide atlas of humoral immunity to <i>Mycobacterium tuberculosis</i> across the spectrum of disease. [PDF]

Front Immunol
Khan MZ, Irvine EB, Cizmeci D, Davies LRL, Randall AZ, Pablo J, Vidal SJ, Lasrado N, Darrah PA, Hsiao JC, Mann C, Nair S, Grace PS, Fontana L, Juelg B, Barouch DH, Restrepo BI, Roederer M, Seder RA, Wallis RS, Churchyard G, Stein CM, Boom WH, Campo JJ, Alter G.   +24 more
europepmc   +1 more source

Bacillus Calmette-Guérin immunotherapy-induced extracellular vesicles promote antitumor immunity in bladder cancer. [PDF]

Front Immunol
Ortiz-Bonilla CJ, Molony RD, Miyamoto H, Messing E, Lee YF.   +4 more
europepmc   +1 more source